Calgary, AB, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Halifax, NS, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Hamilton, ON, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Montreal, QC, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Quebec, QC, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Toronto, ON, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Vancouver, BC, Canada; Research Site:
A Study of NT-Pro Brain Natriuretic Peptide (NT-proBNP) in Patients Presenting With Acute Dyspnea.
Amsterdam, Netherlands; Research Site:
Effect of NT-proBNP guided treatment of Chronic Heart Failure (PRIMA Study).
Delft, Netherlands; Research Site:
Effect of NT-proBNP guided treatment of Chronic Heart Failure (PRIMA Study).
Maastricht, Netherlands; Research Site:
Effect of NT-proBNP guided treatment of Chronic Heart Failure (PRIMA Study).
Rotterdam, Netherlands; Research Site:
Effect of NT-proBNP guided treatment of Chronic Heart Failure (PRIMA Study).
Utrecht, Netherlands; Research Site:
Effect of NT-proBNP guided treatment of Chronic Heart Failure (PRIMA Study).
Venlo, Netherlands; Research Site:
Effect of NT-proBNP guided treatment of Chronic Heart Failure (PRIMA Study).